AbbVie’s blockbuster drug Humira faces patent expirations, but there’s a lot more to it than the immunosuppressive, Teresa Rivas writes in this week’s edition of Barron’s. The company has profitable products that have begun to fill the gap left by Humira’s decline. Investors who preferred to wait out the transition from Humira may have erred — AbbVie stock is up by more than 19%, to a recent $162, so far in 2022. Moreover, the stock looks cheap and has a handsome dividend yield. It’s worth owning-now, the author argues. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie’s (NYSE:ABBV) Loss Could be CVS’s (NYSE:CVS) Gain
- The Top Dividend Stocks to Prepare for Retirement – And How to Choose Them
- The 7 Best Stocks for Retirement
- Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
- AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline